CLN5 Gene - Ceroid Lipofuscinosis, Neuronal 5

CLN5 Gene

Introduction

Cln5 Gene Ceroid Lipofuscinosis, Neuronal 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

{{- <!-- CLN5 Gene Page - Ceroid Lipofuscinosis, Neuronal 5 --> -}} [@schmiedt2011]

<div class="infobox infobox-gene"> [@mole2005]

| Attribute | Value | [@vines2001]
|-----------|-------|
| Gene Symbol | CLN5 |
| Gene Name | Ceroid Lipofuscinosis, Neuronal 5 |
| Official Full Name | CLN5, Lysosomal Trafficking Protein |
| Chromosomal Location | 13q22.3 |
| GRCh38 Coordinates | chr13:77,029,618-77,041,929 |
| NCBI Gene ID | 1203 |
| OMIM ID | 608096 |
| Ensembl ID | ENSG00000157540 |
| UniProt ID | Q9NWW5 |
| Gene Family | CLN5 family |

</div>}

Overview

CLN5 Gene

Introduction

Cln5 Gene Ceroid Lipofuscinosis, Neuronal 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

{{- <!-- CLN5 Gene Page - Ceroid Lipofuscinosis, Neuronal 5 --> -}} [@schmiedt2011]

<div class="infobox infobox-gene"> [@mole2005]

| Attribute | Value | [@vines2001]
|-----------|-------|
| Gene Symbol | CLN5 |
| Gene Name | Ceroid Lipofuscinosis, Neuronal 5 |
| Official Full Name | CLN5, Lysosomal Trafficking Protein |
| Chromosomal Location | 13q22.3 |
| GRCh38 Coordinates | chr13:77,029,618-77,041,929 |
| NCBI Gene ID | 1203 |
| OMIM ID | 608096 |
| Ensembl ID | ENSG00000157540 |
| UniProt ID | Q9NWW5 |
| Gene Family | CLN5 family |

</div>}

Overview

The CLN5 gene encodes a lysosomal protein involved in the pathogenesis of neuronal ceroid lipofuscinosis (NCL). CLN5 is a soluble lysosomal protein that interacts with other NCL proteins to form a complex involved in lysosomal function and autophagy. Mutations in CLN5 cause variant forms of Batten disease, typically with late infantile or juvenile onset^[1].

Function

Protein Structure

CLN5 is a 407-amino acid soluble lysosomal glycoprotein (48 kDa). It contains a signal peptide for secretion and is targeted to lysosomes via mannose-6-phosphate-independent pathways^[2].

Normal Physiological Roles

• Lysosomal Function: Maintains lysosomal enzyme activity
• [Autophagy](/entities/autophagy) Regulation: Participates in autophagic flux
• Protein Trafficking: Mediates lysosomal trafficking
• Neuronal Survival: Essential for neuronal health

Molecular Interactions

CLN5 interacts with:

• CLN8 - ER-lysosomal trafficking
• CLN6 - Lysosomal membrane complex
• Lysosomal enzymes - Activation/trafficking
• CSP (Cysteine String Protein) - Synaptic function

Disease Associations

CLN5 Disease (Variant Late Infantile NCL)

CLN5 mutations cause a form of NCL with variable onset^[1]:

| Feature | Onset | Progression |
|---------|-------|-------------|
| Vision loss | 5-10 years | Progressive retinal degeneration |
| Seizures | 5-10 years | Myoclonic, generalized |
| Cognitive decline | 5-10 years | Progressive dementia |
| Motor dysfunction | 6-12 years | Ataxia, spasticity |
| Speech decline | 6-12 years | Progressive loss |
| Death | 10-20 years | Variable |

Common Mutations

| Mutation | Type | Frequency | Effect |
|----------|------|-----------|--------|
| c.1175_1177delAGA | In-frame deletion | 30% | p.K392del |
| c.391T>C | Missense | 15% | p.Y131H |
| c.526G>A | Missense | 10% | p.D176N |
| c.887G>A | Missense | 8% | p.W296X |
| c.328C>T | Nonsense | 5% | p.R110X |

Genotype-Phenotype Correlations

• Deletion carriers: Classic late infantile phenotype
• Missense/Missense: Variable, often later onset
• Compound heterozygous: Intermediate presentation

Expression Patterns

• Tissue Distribution: High in brain ([cortex](/brain-regions/cortex), cerebellum), retina
• Brain Regions: Predominant in [neurons](/entities/neurons)
• Cellular Localization: Lysosomal lumen
• Developmental Expression: Increases during development
• Transcript: 1.9 kb mRNA, 4 exons

Therapeutic Approaches

Current Treatments

• Anticonvulsants: Seizure management
• Supportive care: Multidisciplinary approach
• Physical/occupational therapy: Maintain function

Experimental Therapies

• Enzyme replacement: Recombinant CLN5 protein
• Gene therapy: AAV-vector delivery in development
• Stem cell therapy: Investigational approaches

Research Directions

Background

The study of Cln5 Gene Ceroid Lipofuscinosis, Neuronal 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [NCBI Gene: CLN5](https://www.ncbi.nlm.nih.gov/gene/1203)
• [OMIM: CLN5](https://www.omim.org/entry/608096)
• [UniProt: Q9NWW5](https://www.uniprot.org/uniprotkb/Q9NWW5)
• [Batten Disease Resource](https://www.bdsra.org/)
• [ClinicalTrials.gov: CLN5](https://clinicaltrials.gov/search?cond=CLN5)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CLN5 Gene - Ceroid Lipofuscinosis, Neuronal 5 discovered through SciDEX knowledge graph analysis: